Pulse Biosciences Q2 net loss narrows to $9.9M; cash $58.7M after $65M private placement

PULSE BIOSCIENCES, INC.

GAAP net loss ($9.9M) vs ($14.0M) YoY; Non-GAAP net loss ($8.5M) vs ($11.9M).
Cash totaled $58.7M at June 30, 2023, up from $14.8M a year ago; Q2 warrant exercises added $14.6M gross.
Closed $65M private placement with Executive Chairman Robert Duggan, cancelling all debt owed to him.
Preclinical: nsPFA cardiac clamp ablates 25mm tissue in 1.25 sec; catheter isolates pulmonary veins in ~5 sec.
First-in-human study of nsPFA for benign thyroid nodules showed positive safety and tissue response.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

PULSE BIOSCIENCES, INC. reported the fiscal quarter ended June 30, 2023 results: net income ($9.9) million.

Period: the fiscal quarter ended June 30, 2023
Net income: ($9.9) million
Result: reported results

Exact text from the filing

GAAP net loss for the three months ended June 30, 2023 was ($9.9) million compared to ($14.0) million for the three months ended June 30, 2022.

View on SEC.gov

Browse all earnings releases →

PULSE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-023047

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.